OCULAR THERAPEUTIX, INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
OCULAR THERAPEUTIX, INC (OCUL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.21% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 1.93%, a 14.60% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-06-30 was 2.03%, a 6.45% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-03-31 was 1.62%, a 29.26% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2014-09-30 was 2.26%.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.21%, a 2.43% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.11%, a 10.48% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.72%, a 77.14% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.10%, a 162.50% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.21% 10-K · filed 2026-02-05 | |||
| 2024-12-31 | 4.11% 10-K · filed 2026-02-05 | |||
| 2023-12-31 | 3.72% 10-K · filed 2026-02-05 | |||
| 2022-12-31 | 2.10% 10-K · filed 2025-03-03 | |||
| 2021-12-31 | 0.80% 10-K · filed 2024-03-11 | |||
| 2020-12-31 | 1.12% 10-K · filed 2023-03-06 | |||
| 2019-12-31 | 2.25% 10-K · filed 2022-02-28 | |||
| 2018-12-31 | 2.65% 10-K · filed 2020-03-12 | |||
| 2017-12-31 | 2.00% 10-K · filed 2020-03-12 | |||
| 2016-12-31 | 1.42% 10-K · filed 2019-03-07 | |||
| 2015-12-31 | 1.67% 10-K · filed 2018-03-08 | |||
| 2015-09-30 | 1.93% 10-Q · filed 2015-11-10 | 1.65% 10-Q · filed 2015-11-10 | ||
| 2015-06-30 | 2.03% 10-Q · filed 2015-08-10 | 1.64% 10-Q · filed 2015-08-10 | ||
| 2015-03-31 | 1.62% 10-Q · filed 2015-05-15 | |||
| 2014-12-31 | 2.24% 10-K · filed 2017-03-10 | |||
| 2014-09-30 | 2.26% 10-Q · filed 2015-11-10 | 2.24% 10-Q · filed 2015-11-10 | ||
| 2014-06-30 | 2.17% 10-Q · filed 2015-08-10 | 2.24% 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | 2.29% 10-Q · filed 2015-05-15 | |||
| 2013-12-31 | 1.23% 10-K · filed 2016-03-10 | |||
| 2012-12-31 | 1.51% 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |